Literature DB >> 16462491

Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.

Oszkar Szentirmai1, Cheryl H Baker, Ning Lin, Szofia Szucs, Masaya Takahashi, Shigeru Kiryu, Andrew L Kung, Richard C Mulligan, Bob S Carter.   

Abstract

OBJECTIVE: Outcome studies in rodent tumor models rely on both histological and noninvasive study end points. Intracranial models require special tools to observe tumor growth over time noninvasively, such as magnetic resonance imaging (MRI), computed tomographic scanning, or cranial window techniques. These techniques share disadvantages in terms of cost, technical expertise required, and overall animal throughput for analysis. In this report, we sought to validate the use of the relatively newer technique of bioluminescence imaging (BLI) of intracranial glioblastoma xenograft growth by comparing it with gadolinium-enhanced MRI.
METHODS: U87MG glioma cell lines genetically engineered to express the firefly luciferase gene were stereotactically injected into nude mice in the left frontal lobe. Weekly BLI and MRI were performed after the inoculation of tumor cells. For BLI, tumor growth was assessed as the peak BLI after systemic injection of luciferin substrate. MRI-based growth curves were created by three-dimensional volumetric reconstruction of axial gadolinium-enhanced MRI data covering the whole brain. In a separate experiment, mice were treated with adenoviruses encoding antiangiogenic soluble vascular endothelial growth factor receptors, and treatment effect was monitored by BLI.
RESULTS: Untreated tumor growth was readily detected and observed over time by serial BLI measurements. Furthermore, tumor-derived light emission was highly correlated with volume of tumor as assessed by MRI. Furthermore, the tested antiangiogenic treatment effect was readily detected using this technique, suggesting the power of the technique for sensitive monitoring of novel therapeutics.
CONCLUSION: BLI offers a simple and rapid technique for assessing intracranial glioblastoma growth in rodent models noninvasively, which correlates well with MRI. The speed of the BLI technique can increase experimental throughput, allows for targeted histological analysis in animals showing the greatest treatment effects, and provides new insights into the kinetics of intracranial tumor growth in the setting of different treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462491     DOI: 10.1227/01.NEU.0000195114.24819.4F

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  52 in total

1.  Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging.

Authors:  Guifa Xi; Veena Rajaram; Babara Mania-Farnell; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  Childs Nerv Syst       Date:  2012-01-27       Impact factor: 1.475

2.  Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation.

Authors:  Mackenzie C McGee; J Blair Hamner; Regan F Williams; Shannon F Rosati; Thomas L Sims; Catherine Y Ng; M Waleed Gaber; Christopher Calabrese; Jianrong Wu; Amit C Nathwani; Christopher Duntsch; Thomas E Merchant; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04       Impact factor: 7.038

Review 3.  Noninvasive molecular neuroimaging using reporter genes: part II, experimental, current, and future applications.

Authors:  T F Massoud; A Singh; S S Gambhir
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-13       Impact factor: 3.825

4.  MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.

Authors:  Michal Grzmil; Roland M Huber; Daniel Hess; Stephan Frank; Debby Hynx; Gerald Moncayo; Dominique Klein; Adrian Merlo; Brian A Hemmings
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

5.  A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.

Authors:  David S Ziegler; Joanna Keating; Santosh Kesari; Eva M Fast; Leigh Zawel; Naren Ramakrishna; Jessica Barnes; Mark W Kieran; Sophie E M Veldhuijzen van Zanten; Andrew L Kung
Journal:  Neuro Oncol       Date:  2011-07-01       Impact factor: 12.300

6.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Authors:  Tommy Alain; XueQing Lun; Yvan Martineau; Polen Sean; Bali Pulendran; Emmanuel Petroulakis; Franz J Zemp; Chantal G Lemay; Dominic Roy; John C Bell; George Thomas; Sara C Kozma; Peter A Forsyth; Mauro Costa-Mattioli; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

Authors:  David S Ziegler; Renee D Wright; Santosh Kesari; Madeleine E Lemieux; Mary A Tran; Monish Jain; Leigh Zawel; Andrew L Kung
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

8.  In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.

Authors:  W Maes; C Deroose; V Reumers; O Krylyshkina; R Gijsbers; V Baekelandt; J Ceuppens; Z Debyser; S W Van Gool
Journal:  J Neurooncol       Date:  2008-09-12       Impact factor: 4.130

9.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma.

Authors:  Szofia S Bullain; Ayguen Sahin; Oszkar Szentirmai; Carlos Sanchez; Ning Lin; Elizabeth Baratta; Peter Waterman; Ralph Weissleder; Richard C Mulligan; Bob S Carter
Journal:  J Neurooncol       Date:  2009-04-23       Impact factor: 4.130

10.  Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.

Authors:  Seung-Ho Yang; Yong-Kil Hong; Sin-Soo Jeun; Il Sup Kim; Jae Taek Hong; Jae Hoon Sung; Byung Chul Son; Sang Won Lee; Moon-Chan Kim; Kwan-Sung Lee
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.